Medplus Subsidiary Optival Health Solutions Receives Drug License Suspension Order in Maharashtra
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has had its drug license suspended for a store in Ahmednagar, Maharashtra, for ten days. The suspension, effective from December 19, 2025, is due to alleged violations of the Drugs and Cosmetics Act and Rules. A potential revenue loss of ₹2.00 lacs is anticipated.
The impact is considered low as it affects a single store for a limited period of ten days and the quantifiable financial impact (₹2.00 lacs) is relatively small compared to the company's overall operations.
The announcement details a suspension of a drug license for a subsidiary's store, which is a negative event that could impact operations and revenue.
Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for the drug license of one of its stores located in Maharashtra.
The suspension order was issued by the Asst. Commissioner & Licensing authority, Food & Drug Administrations, Ahmednagar, Maharashtra. The drug license for the store situated at Bhandari Colony, Ahmednagar, Maharashtra, has been suspended for a period of ten days.
The company received the order on December 19, 2025. The suspension is reportedly due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The potential revenue loss due to this suspension is estimated at ₹2.00 lacs.
This update is provided in accordance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The information will be made available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Ltd.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.